Werfen Introduces GEM Premier 7000 with iQM3 Blood Gas Testing System

As the number one source of preanalytical error, hemolysis accounts for up to 70% of all such errors. Despite its prevalence throughout the hospital, hemolysis is not visible in whole blood, and can often go unrecognized. The consequences of in vitro hemolysis can include inappropriate patient management, increased length of stay, and increased costs, among others. At this year’s ADLM Annual Meeting, Werfen is introducing the GEM Premier 7000 with Intelligent Quality Management 3 (iQM3), a breakthrough in blood gas testing that detects hemolysis at the POC.

The GEM Premier 7000 with iQM3 is a portable critical care system for use by health care professionals to rapidly analyze lithium heparinized whole blood samples at the point of health care delivery in a clinical setting and a central laboratory. The instrument provides quantitative measurements of pH, pCO2, pO2, sodium, potassium, chloride, ionized calcium, glucose, lactate, hematocrit, total bilirubin, and CO-Oximetry (tHb, O2Hb, COHb, MetHb, HHb, sO2) parameters from arterial, venous, or capillary lithium heparinized whole blood. These parameters, along with derived parameters, aid in the diagnosis of a patient’s acid/base status, electrolyte and metabolite balance and oxygen delivery capacity.

Werfen is providing a virtual reality laboratory experience to visitors at its booth where they can see 3D customized layouts of HemoCell specialized lab automation workcells for hemostasis labs of all sizes, shapes, and volumes. They can also see how Werfen’s comprehensive autoimmune diagnostics solution can help advance a lab’s capabilities by optimizing efficiency and enhancing clinical decision-making. Additionally, Werfen is presenting an industry workshop titled, Challenges in Pre-Analytical Error Detection: Impact of Hemolysis and Potential Solutions. The workshop will focus on the challenges in pre-analytical error detection, including hemolysis, its prevalence, and its impact on potassium and clinical outcomes. Current strategies and the company’s new technology to detect hemolysis for mitigating risks at the POC will also be discussed.

Related Links:
Werfen